Post-treatment PET scans can reassure cervical cancer patients

"This is the first time we can say that we have a reliable test to follow cervical cancer patients after therapy," says Julie K. Schwarz, M.D., Ph.D., a Barnes-Jewish Hospital resident in the Department of Radiation Oncology. "We ask them to come back for a follow-up visit about three months after treatment is finished, and we perform a PET scan. If the scan shows a complete response to treatment, we can say with confidence that they are going to do extremely well. That's really powerful."

Schwarz and colleagues published their study in the Nov. 21, 2007 issue of the Journal of the American Medical Association (JAMA).

Without a test like PET, it can be difficult to tell whether treatment has eliminated cervical tumors, Schwarz says. That's because small tumors are hard to detect with pelvic exams, and overt symptoms, such as leg swelling, don't occur until tumors grow quite large. Furthermore, CT and MRI scans often don't differentiate tumor tissue from surrounding tissues, Pap tests can be inaccurate because of tissue changes induced by radiation therapy, and no blood test exists to detect the presence of cervical cancer.

Cancerous tumors glow brightly in the PET scans used in the study, called FDG-PET scans, which detect emissions from radioactively tagged blood sugar, or glucose. Tumor tissue traps more of the glucose than does normal tissue, making tumors readily discernable.

Not only can post-treatment PET scans reassure those patients whose tumors respond well to therapy, they can also identify those patients whose tumors have not responded so that their physicians can explore other treatment options before the cancer advances further. These options can include surgery to remove tissue, standard chemotherapy or experimental therapies available through clinical trials.

"Follow-up PET scans can also be very useful tools for physicians conducting clinical trials of new therapies," Schwarz says. "Our study has shown that the scans are predictive of long-term survival. Using PET scans, clinical researchers can get an early readout of how effective experimental treatments might be."

Schwarz and colleagues also have a project to compare follow-up PET results with tumor biology to find out why some tumors don't respond well to therapy. In a study that won her a Resident Clinical Basic Science Research Award from the American Society for Therapeutic Radiation and Oncology, a global organization of medical professionals, Schwarz found differences in gene activity between tumors from patients that responded well and those that had persistent disease. Ongoing research will look for the significance of these differences.

The study's senior author, Perry Grigsby, M.D., professor of radiation oncology, of nuclear medicine and of obstetrics and gynecology and a radiation oncologist with the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, has overseen a patient database that now has PET images and tumor samples from hundreds of cervical cancer patients.

"We have a tremendous database of PET images collected from patients in the department since 1998," Schwarz says. "We want to combine these results with analyses of tumor biopsies so that we can more effectively choose additional therapies for patients who haven't responded to the initial treatment."

Source: Washington University in St. Louis

Dual-Mode Nanoparticles Image Tumors Using MRI and PET
Medical imaging represents one of the most used and useful procedures in the oncologist’s diagnostic toolkit, even though each of the most useful techniques—magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning—has its own set of limitations.
Patient's own infection-fighting T cells put late-stage melanoma into long-term remission
Case is first to show safety and effectiveness of using cloned cells alone to kill tumors
Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.
Researchers develop new PET scanning probe that will allowing monitoring of the immune system
Researchers at UCLA's Jonsson Comprehensive Cancer Center have modified a common chemotherapy drug to create a new probe for Positron Emission Tomography (PET), an advance that will allow them to model and measure the immune system in action and monitor response to new therapies.
Bone drug could help prevent the spread of breast cancer
Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.
Made-to-order isotopes hold promise on science's frontier
Designer labels have a lot of cachet -- a principle that’s equally true in fashion and physics. The future of nuclear physics is in designer isotopes -- the relatively new power scientists have to make specific rare isotopes to solve scientific problems and open doors to new technologies, according to Bradley Sherrill, a University Distinguished Professor of physics and associate director for research at the National Superconducting Cyclotron Laboratory at Michigan State University.
Scans spot hidden tumors in rare cancer syndrome
Researchers at Dana-Farber Cancer Institute report that full-body PET/CT scanning detected unsuspected, treatable tumors in 3 of 15 patients with Li-Fraumeni syndrome (LFS), a rare genetic cancer syndrome for which no screening tests have been recommended.
Radioactive 'Understudy' May Aid Medical Imaging, Drug Development
Broadway stars have understudies. Now, an increasingly popular radioactive isotope has its own stand-in. Developed in part by researchers at the National Institute of Standards and Technology, the substance might ultimately improve medical imaging, speed up clinical trials of many drugs and facilitate efforts to develop more individualized medical treatment.
Quantitative PET imaging finds early determination of effectiveness of cancer treatment
With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient’s response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors. Researchers have found that measuring a quantitative index—one that reflects the reduction of metabolic activity after chemotherapy first begins—adds accurate information about patients’ responses to first-line chemotherapy, according to a study in the October issue of the Journal of Nuclear Medicine.

Post-treatment PET scans can reassure cervical cancer patients

Related stories:

News discussion: